专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5310653A Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis 失效
标题翻译：肿瘤标志物蛋白及其抗体用于癌症风险评估或诊断
公开(公告)号：US5310653A
公开(公告)日：1994-05-10
申请号：US12972
申请日：1993-02-02
申请人： Margaret Hanausek-Walaszek , Thomas J. Slaga , Zbigniew Walaszek
发明人： Margaret Hanausek-Walaszek , Thomas J. Slaga , Zbigniew Walaszek
IPC分类号： C07K14/47 , C07K16/18 , G01N33/574 , A61K37/08 , A61K39/00 , C07K15/18
CPC分类号： G01N33/57476 , C07K14/47 , C07K16/18 , G01N33/5743 , G01N33/57438 , G01N33/57496
摘要： A tumor-associated marker protein was purified and antibodies thereto developed for cancer diagnosis and assessment of cancer risk associated with the long-term use of synthetic steroid hormones, both contraceptive and non-contraceptive, and other drugs that exhibit tumor promotional properties. The marker protein and antibodies thereto provided are interspecies immunologically cross-reactive.In summary, the marker p65 tumor-associated factor of the present invention has the following characteristics:(a) binds substantially completely to a phenyl hydrophobic interaction column in a buffer containing 20% ammonium sulfate and eluted at ca. 16% ammonium sulfate;(b) localized primarily in the nuclear envelopes with only small amounts present in the cytoplasm from where is released to the blood circulation in vivo or cell culture medium in vitro;(c) induced in normal, adult tissues by chemical carcinogens (initiators) but not by tumor promoters, the carcinogen-induced production being enhanced by the latter.Also disclosed herein are processes for purifying the 65 kDa tumor marker from plasma, tumor cytosol or ascitic fluid of carcinoma bearing animals; processes for producing antisera and purified antibody preparations to the 65 kDa tumor marker; and methods using antibody to the 65 kDa to diagnose or assess the likelihood of cancer.
摘要翻译：纯化了与肿瘤相关的标记蛋白，并且其抗体开发用于癌症诊断和评估与长期使用合成类固醇激素（避孕和非避孕药）以及其它展现肿瘤促进性质的药物相关的癌症风险。标记蛋白及其提供的抗体是免疫交叉反应性的种间。总之，本发明的标记p65肿瘤相关因子具有以下特征：（a）基本上完全与含有20％硫酸铵的缓冲液中的苯基疏水相互作用柱结合并在约5℃下洗脱。 16％硫酸铵; （b）主要在核包膜中定位，其中只有少量存在于细胞质中，其体内释放到体内血液循环或体外细胞培养基; （c）通过化学致癌物（引发剂）而不是由肿瘤启动子在正常的成年组织中诱导，致癌物诱导的生产由后者增强。本文还公开了从承载动物的血浆，肿瘤细胞质或腹水中纯化65kDa肿瘤标志物的方法; 制备抗血清和纯化抗体制剂至65kDa肿瘤标志物的方法; 以及使用65kDa抗体诊断或评估癌症可能性的方法。

2. 发明授权

US4199502A Removal of heparin from blood plasma samples using an insoluble protamine reaction product 失效
标题翻译：使用不溶性鱼精蛋白反应产物从血浆样品中除去肝素
公开(公告)号：US4199502A
公开(公告)日：1980-04-22
申请号：US931033
申请日：1978-08-04
申请人： Arthur L. Babson , James E. Turner
发明人： Arthur L. Babson , James E. Turner
IPC分类号： C08B37/10 , G01N33/86 , C07G7/00 , A61K37/08
CPC分类号： C08B37/0075 , G01N33/86 , G01N2400/40
摘要： This invention relates to a method for the removal of heparin from heparin-containing blood plasma test samples using an insoluble protamine reaction product, without adversely affecting subsequent testing of the plasma for clotting time. Protamine sulfate or a combination of protamine sulfate and serum albumin is cross-linked with glutaraldehyde to form an insoluble reaction product which is capable of adsorbing heparin. According to the method of this invention, excess amounts of either of the cross-linked protamine reaction products are added to blood plasma samples containing heparin and the mixture is agitated for a time sufficient to permit adsorption of substantially all heparin present. The insoluble protamine heparin complex formed is removed from the plasma along with any excess insoluble protamine reaction product. Aliquots of the heparin-free plasma may be subjected to coagulation tests in order to determine true clotting time.
摘要翻译：本发明涉及使用不溶性鱼精蛋白反应产物从含肝素血浆试验样品中除去肝素的方法，而不会不利地影响随后的血浆凝固时间的测试。将硫酸鱼精蛋白或硫酸鱼精蛋白和血清白蛋白的组合与戊二醛交联以形成能够吸附肝素的不溶性反应产物。根据本发明的方法，将过量的交联的鱼精蛋白反应产物加入到含有肝素的血浆样品中，并将混合物搅拌足以允许存在基本上所有肝素的吸附。形成的不溶性鱼精蛋白肝素复合物与任何过量的不溶性鱼精蛋白反应产物一起从血浆中除去。可以对无肝素血浆的等分试样进行凝血试验，以确定真正的凝血时间。

3. 发明授权

US4749689A Hemostatic agent composed of collagen/gelatin and protamine 失效
标题翻译：止血剂由胶原/明胶和鱼精蛋白组成
公开(公告)号：US4749689A
公开(公告)日：1988-06-07
申请号：US87966
申请日：1987-08-17
申请人： Teruo Miyata , Kazuhiko Kodaira , Masayasu Furuse , Yasuharu Noishiki
发明人： Teruo Miyata , Kazuhiko Kodaira , Masayasu Furuse , Yasuharu Noishiki
IPC分类号： A61K38/16 , A61K38/17 , A61K38/39 , A61L15/12 , A61L26/00 , A61K37/08 , A61L15/01 , A61L17/00 , C08L89/06
CPC分类号： A61L15/125 , A61K38/39 , A61L26/0052 , A61L2400/04 , Y10S128/08
摘要： This invention relates to a hemostatic agent used in surgical operations, which can be produced in two ways: one blending collagen/gelatin with protamine, the other blending collagen/gelatin with protamine and a bi-functional cross-linking agent so as to make said collagen/gelatin have a covalent bond with said protamine. The produced hemostatic agent can stop bleeding within far less time than a conventional hemostatic agent made out of pure collagen.
摘要翻译：本发明涉及用于外科手术的止血剂，其可以以两种方式制备：一种将胶原蛋白/明胶与鱼精蛋白混合，另一种将胶原/明胶与鱼精蛋白混合和双功能交联剂混合制成所述胶原/明胶与所述鱼精蛋白具有共价键。所生产的止血剂可以在比由纯胶原制成的常规止血剂的时间更短的时间内止血。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式